受体导向药物L-HAS-Ara-AMP抗HBV效应的临床研究 |
| |
引用本文: | 王慧芬,张玲霞,王小明,赵敏,李莉,石建时,周艳贤.受体导向药物L-HAS-Ara-AMP抗HBV效应的临床研究[J].中国新药杂志,1999,8(12). |
| |
作者姓名: | 王慧芬 张玲霞 王小明 赵敏 李莉 石建时 周艳贤 |
| |
作者单位: | 解放军302医院感染四科,北京100039 |
| |
摘 要: | 目的:观察去唾液酸糖蛋白受体导向药物LHASAra-AMP的抗HBv临床疗效。方法:应用5 d和28 d疗程治疗慢性乙型肝炎29例,以Ara-AMP治疗27例为对照。结果:L-HSA-Ara-AMP 5 d疗程,10例HBeAg阳性阴转3例,8例HBV-DNA阳性阴转4例。28 d疗程HBeAg阴转率31.6%,HBeAg滴度下降率47.4%,有治疗效应者79.0%;HBV-DNA阴转率31.6%。5 d疗程治疗结束1月时部分HBeAg和HBV-DNA已复阳。28 d疗程治疗结束3月时阴转的病例仍为阴性。LHSA-Ara-AMP组未发现任何不良反应。结论:LHSA-Ara-AMP组的Ara-AMP实际用量大大减少仍具有与单用Ara-AMP相似或略优的抗病毒效果,并且毒副作用减少。
|
关 键 词: | 导向治疗 乙型肝炎 |
CLINICAL STUDY ON THE ANTI-HBV EFFECT OF L-HAS-Ara-AMP-A RECEPTOR TARGETED DRUG |
| |
Abstract: | OBJECTIVE:To observe the clinical efficacy of L-HAS-Ara-AMP (lactoaminated human serum albumin arabinoside adenine monophosphate), a receptor targeted drug. METHODS: 56 patients with chronic hepatitis B were entered into the study. 29 of them were treated with L-HASAra-AMP in a daily dose of 35 mg/kg for 5 days or 28 days;the rest were used as control and treated with Ara-AMP in a daily dose of 10 mg/kg. RESULTS:In the 5 days group, there are 10 patients with positive HBeAg and 8 patients with positive HBV-DNA,after treatment 3 of the former and 4 of the later temporaryly turned into negative and reversed a month later. In the 28 days group, a HBeAg negative-turning rate of 31.65 % ,a HBeAg titer decresing rate of 47.4 %, and an effective rate of 79.0% were obtained after treatment, these parameters didn' t reversed even 3 months later. No adverse rections were observed. CONCLUSION:L-HAS-Ara-AMP is effective in treatment of HBV infections and its anti-viral activity even in very low doses is more powerful than that of free Ara-AMP with no obvious side effects. |
| |
Keywords: | Targeting treatment Chronic hepatitis B |
本文献已被 万方数据 等数据库收录! |
|